William Phillips, MD, discusses real-world findings on RET inhibitor dose reductions and clinical outcomes in advanced RET fusion–positive NSCLC.
William Phillips, MD
Advertisement
Articles by William Phillips, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
3
FDA Approves Lirafugratinib for Pretreated, Locally Advanced or Metastatic Cholangiocarcinoma
4
Dr Voorhees on Eligibility Criteria for the CERVINO Trial in Multiple Myeloma
5